X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20238) 20238
Book Review (2298) 2298
Newsletter (1098) 1098
Publication (1044) 1044
Conference Proceeding (185) 185
Newspaper Article (154) 154
Book Chapter (50) 50
Transcript (24) 24
Dissertation (23) 23
Magazine Article (8) 8
Trade Publication Article (5) 5
Book / eBook (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Presentation (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15849) 15849
humans (14797) 14797
carboplatin (12905) 12905
oncology (11302) 11302
female (10872) 10872
chemotherapy (8547) 8547
middle aged (7958) 7958
antineoplastic combined chemotherapy protocols - therapeutic use (7612) 7612
male (7470) 7470
carboplatin - administration & dosage (7436) 7436
aged (6976) 6976
adult (6291) 6291
cancer (6144) 6144
cisplatin (5487) 5487
paclitaxel (4185) 4185
treatment outcome (3835) 3835
lung neoplasms - drug therapy (3800) 3800
paclitaxel - administration & dosage (3264) 3264
antineoplastic combined chemotherapy protocols - adverse effects (3022) 3022
carcinoma, non-small-cell lung - drug therapy (2841) 2841
neoplasm staging (2837) 2837
cisplatin - administration & dosage (2649) 2649
ovarian neoplasms - drug therapy (2598) 2598
care and treatment (2549) 2549
carboplatin - adverse effects (2408) 2408
carcinoma (2408) 2408
combined modality therapy (2363) 2363
antineoplastic agents - therapeutic use (2352) 2352
carboplatin - therapeutic use (2263) 2263
ovarian cancer (2209) 2209
aged, 80 and over (2193) 2193
disease-free survival (2040) 2040
prognosis (2012) 2012
research (2003) 2003
lung neoplasms - pathology (1994) 1994
survival rate (1982) 1982
trial (1909) 1909
retrospective studies (1897) 1897
survival (1853) 1853
therapy (1824) 1824
etoposide - administration & dosage (1744) 1744
animals (1717) 1717
drug administration schedule (1711) 1711
radiotherapy (1695) 1695
antineoplastic combined chemotherapy protocols - administration & dosage (1626) 1626
survival analysis (1594) 1594
pharmacology & pharmacy (1590) 1590
antineoplastic agents - administration & dosage (1535) 1535
tumors (1518) 1518
carcinoma, non-small-cell lung - pathology (1438) 1438
lung cancer (1435) 1435
obstetrics & gynecology (1432) 1432
gemcitabine (1399) 1399
etoposide (1392) 1392
antineoplastic agents (1349) 1349
combination (1343) 1343
lung cancer, non-small cell (1335) 1335
analysis (1328) 1328
hematology, oncology and palliative medicine (1290) 1290
ovarian neoplasms - pathology (1269) 1269
follow-up studies (1262) 1262
antimitotic agents (1233) 1233
dose-response relationship, drug (1225) 1225
respiratory system (1215) 1215
medicine & public health (1214) 1214
phase-ii (1193) 1193
antineoplastic agents - adverse effects (1192) 1192
surgery (1167) 1167
bevacizumab (1154) 1154
deoxycytidine - analogs & derivatives (1150) 1150
toxicity (1123) 1123
lung neoplasms - mortality (1105) 1105
docetaxel (1099) 1099
drug therapy (1082) 1082
adolescent (1076) 1076
cyclophosphamide (1076) 1076
chemotherapy, adjuvant (1061) 1061
phase-iii trial (1058) 1058
metastasis (1033) 1033
platinum (1028) 1028
health aspects (1017) 1017
non-small cell lung cancer (1007) 1007
deoxycytidine - administration & dosage (968) 968
patients (920) 920
cisplatin - therapeutic use (913) 913
clinical trials (904) 904
abridged index medicus (903) 903
antineoplastic agents - pharmacology (899) 899
cyclophosphamide - administration & dosage (895) 895
oncology, experimental (895) 895
cancer therapies (893) 893
carboplatin - pharmacology (893) 893
paclitaxel - adverse effects (891) 891
carcinoma, non-small-cell lung - mortality (884) 884
cell lung-cancer (879) 879
hematology (876) 876
time factors (842) 842
child (839) 839
randomized-trial (838) 838
prospective studies (828) 828
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20023) 20023
Japanese (584) 584
French (330) 330
German (282) 282
Chinese (190) 190
Spanish (81) 81
Italian (53) 53
Russian (35) 35
Korean (33) 33
Polish (26) 26
Hungarian (15) 15
Czech (13) 13
Dutch (10) 10
Portuguese (10) 10
Turkish (6) 6
Serbian (4) 4
Lithuanian (3) 3
Romanian (3) 3
Danish (2) 2
Finnish (2) 2
Hebrew (2) 2
Persian (2) 2
Slovak (2) 2
Arabic (1) 1
Bulgarian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2017, Volume 16, Issue 2, pp. 376 - 387
We report progress on predicting tumor response to platinum-based chemotherapy with a novel mass spectrometry approach. Fourteen bladder cancer patients were... 
LUNG | REPAIR | DICARBOXYLATE PLATINUM(II) | CISPLATIN | ONCOLOGY | TUMOR RESPONSE | PERIPHERAL-BLOOD | CLINICAL PHARMACOKINETICS | CANCER | GEMCITABINE | ERCC1 EXPRESSION | Neoplasms - metabolism | Urinary Bladder Neoplasms - diagnosis | Humans | Platinum - pharmacokinetics | Drug Resistance, Neoplasm | Carboplatin - pharmacokinetics | Neoplasms - diagnosis | Antineoplastic Agents - administration & dosage | Platinum - administration & dosage | DNA Adducts - metabolism | Carboplatin - adverse effects | Deoxycytidine - pharmacokinetics | Antineoplastic Agents - adverse effects | Mass Spectrometry | Female | Antineoplastic Agents - pharmacokinetics | DNA Adducts - blood | Urinary Bladder Neoplasms - metabolism | Disease Models, Animal | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Carboplatin - blood | Neoplasms - mortality | Urinary Bladder Neoplasms - drug therapy | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Carboplatin - metabolism | Animals | DNA Repair | Biomarkers | Cell Line, Tumor | Mice | Mutation | Platinum - adverse effects | Deoxycytidine - analogs & derivatives | Drugs | Spectroscopy | Animal models | Gemcitabine | Toxicity | Bladder | Mass spectroscopy | Patients | Bladder cancer | Chemotherapy | Urinary bladder | Platinum | Xenografts | Carboplatin | Scientific imaging | Bioindicators | Diagnostic systems | DNA adducts | Mass spectrometry | Deoxyribonucleic acid--DNA | Adducts | Cancer | Index Medicus | chemotherapy resistance | patient derived xenografts | diagnostic microdosing | BASIC BIOLOGICAL SCIENCES | accelerator mass spectrometry | bladder cancer
Journal Article
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5.5, pp. 652 - 654
Although not yet practice changing in early-stage triple-negative breast cancer, growing evidence suggests that neoadjuvant platinum-based therapy is active... 
CARBOPLATIN | ONCOLOGY
Journal Article
Journal of neuro-oncology, ISSN 0167-594X, 09/2019, pp. 1 - 1
In the original article, the names of authors Mariantonia Carosi and Tatiana Koudriavtseva were incorrectly captured, and author Francesco Cognetti's... 
Carboplatin | Index Medicus
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Biomaterials, ISSN 0142-9612, 01/2018, Volume 151, pp. 38 - 52
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 23, pp. 3120 - 3125
Purpose Cancer and Leukemia Group B conducted a randomized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent... 
PLUS CHEMOTHERAPY | THERAPY | CISPLATIN | ONCOLOGY | CHEMORADIATION | CHEMORADIOTHERAPY | RADIOTHERAPY | COMBINATION | DOCETAXEL | GEMCITABINE | Carcinoma, Non-Small-Cell Lung - radiotherapy | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Lung Neoplasms - radiotherapy | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized | Carboplatin - therapeutic use | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Cetuximab | Guanine - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Combined Modality Therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Guanine - administration & dosage | Adenocarcinoma | Chemotherapy | Carcinoma | Toxicity | Leukemia | Lung cancer | Carboplatin | Clinical trials | Thorax | Survival | Age | Index Medicus | Original Reports | Thor6
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 25, pp. 2969 - 2979
Journal Article
Journal Article
Zhongliu Fangzhi Yanjiu = Cancer Research on Prevention and Treatment, ISSN 1000-8578, 03/2019, Volume 46, Issue 3, p. 285